Practice Update: Haematology & Oncology

VOL. 1 • No. 2 • 2016

RESEARCH NEWS AND VIEWS FROM ELSEVIER

FORMERLY HAEMATOLOGY & ONCOLOGY NEWS

Readers Poll Where do you get your daily medical news from? Scan this code or go to https://goo.gl/PgfEka to have your say in this issue’s PracticeUpdate Haematology & Oncology Readers Poll.

Undetermined: Whether lung cancer patients with autoimmune disease are candidates for immunotherapy

OPINION

There are a number of other small molecules that have been tested in CLL. We’ll see as we combine some of these small molecules if potentially we could shy away from chemotherapy in that disease. DR ANDRE GOY 10

COLON ESMO has released new consensus guidelines for the management of metastatic colorectal cancer that reflect an increasingly personalised approach to treatment.

Given the promise of cancer immunotherapy and the wide

prevalence of autoimmune diagnoses among lung cancer patients, research to determine whether these patients are candidates for such treatment is warranted. This conclusion, based on results of a database quantification of lung cancer patients with autoimmune conditions was presented at the 2016 Annual Meeting of the American Society of Clinical Oncology, from June 3–7.

5

LUNG First-line therapy with

nivolumab plus ipilimumab has demonstrated clinical activity and manageable safety in advanced non-small-cell lung cancer in the phase 1 CheckMate 012 trial, results reported at ASCO show.

8

15

CONFERENCE ASCO 2016

A genomic classifier leads to better decision making about salvage radiotherapy for local prostate cancer recurrence. Double stem cell transplant improves outcomes for children with high-risk neuroblastoma. Image-guided thermal ablation is proven safe and effective in T1a renal cell carcinoma.

14

Angiotensin II antagonist treatment with candesartan in patients with early breast cancer JAMA Oncology The results of the study suggest that the use of candesartan does not protect against trastuzumab-related cardiotoxic effects.

Outcome according to KRAS-, NRAS-, BRAF-, and KRAS variant mutations in metastatic colorectal cancer Annals of Oncology In patients with metastatic colorectal cancer, mutations in KRAS and BRAF are associated with shorter PFS and OS.

Lenalidomide plus dexamethasone vs observation in patients with high-risk smoldering multiple myeloma The Lancet Oncology Early treatment with Rd in selected high- risk SMM patients offers TTP benefit, arguing against observation alone in this population. 10

Inotuzumab ozogamicin for acute lymphoblastic leukaemia The New England Journal of Medicine Inotuzumab ozogamicin therapy was superior to standard therapy in patients with acute lymphoblastic leukaemia;

18

19

however, there was a higher risk of veno-occlusive liver disease associated with it.

2

5

11

Made with